Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use
暂无分享,去创建一个
N. Magné | Cyrus Chargari | J. Spano | A. Levy | Y. Merrouche | J. Guy | A. Lévy
[1] S. Steinberg,et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] É. Oksenhendler,et al. The spectrum of malignancies in HIV‐infected patients in 2006 in France: The ONCOVIH study , 2011, International journal of cancer.
[3] J. Gottdiener,et al. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. , 2011, Clinical Infectious Diseases.
[4] Cyrus Chargari,et al. Inhibitors of Angiogenesis: New Hopes for Oncologists, New Challenges for Anesthesiologists , 2010, Anesthesiology.
[5] Shenhong Wu,et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.
[6] É. Oksenhendler,et al. AIDS-related malignancies: state of the art and therapeutic challenges. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] U. Tirelli,et al. Bevacizumab plus Irinotecan-, Fluorouracil-, and Leucovorin-Based Chemotherapy with Concomitant HAART in an HIV-Positive Patient with Metastatic Colorectal Cancer , 2008, Oncology Research and Treatment.
[8] L. Lekakis,et al. First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: a case report. , 2008, European Journal of Gastroenterology and Hepathology.
[9] D. McDonald,et al. Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.
[10] R. Beart,et al. Colorectal cancer in HIV-infected patients: a case control study , 2007, International Journal of Colorectal Disease.
[11] O. Mir,et al. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? , 2007, Journal of the National Cancer Institute.
[12] Kholoud Porter,et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.
[13] I. Zachary,et al. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. , 2001, Cardiovascular research.
[14] V. Weinberg,et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. , 1999, International journal of radiation oncology, biology, physics.
[15] J. V. Von Roenn,et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. , 1997, The New England journal of medicine.